April W. Armstrong, MD, MPH, Professor and Chief of Dermatology at University of California Los Angeles (UCLA), reviews the latest data on zasocitinib (Takeda) in psoriasis from the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, including results of the Phase 3 LATITUDE Atlas head-to-head study comparing the next-generation tyrosine kinase 2 (TYK2) inhibitor to deucravacitinib (Sotyktu, BMS) in adults with moderate-to-severe plaque psoriasis.